Q4 2024 Earnings Call Transcript March 6, 2025 Arcturus Therapeutics Holdings Inc. misses on earnings expectations. Reported EPS is $-1.11 EPS, expectations were $-0.33. Operator: Good day, everyone, ...

and welcome to Arcturus Therapeutics quarterly financial update and pipeline progress call. Today's call will be led by Joe Payne, our President and CEO; and Andy Sassine, our CFO. Dr. Pad ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities ...

Joseph Payne; President, Chief Executive Officer, Director; Arcturus Therapeutics Holdings Inc Andrew Sassine; Chief Financial Officer, Director; Arcturus Therapeutics Holdings Inc Padmanabh Chivukula ...

Dr. Slaoui is currently on the Company’s Board of Directors, a position he has held since June 2024. Arcturus’ primary revenue streams include license fees, consulting and related technology ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

As Rare Disease Day is commemorated on 28 February, experts discuss the barriers to gene therapy access for some rare ...

Dr. Slaoui is currently on the Company’s Board of Directors, a position he has held since June 2024. Arcturus’ primary revenue streams include license fees, consulting and related technology transfer ...

Prior to joining METiS, he served as President of Arcturus Therapeutics ... “We are excited to welcome Mark Herbert to METiS,” said Dr. Chris Lai, Co-founder & CEO of METiS Pharmaceuticals. “Mark is a ...